Lainie P. Martin

Also affiliated with Hospital of the University of Pennsylvania, University of Pennsylvania

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study”.

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of Clinical Oncology(2024)10.1200/jco.23.02076

N/A

0.644DataRank · unranked

20 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.07.008

N/A

0.208DataRank · unranked

3 citations

Ashley Haggerty, Stefan M. Gysler, Sarah E. Taylor, Kian Behbakht, Jill Alldredge +10 more

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5501

N/A

0DataRank · unranked

9 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2444

N/A

0DataRank · unranked

79 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5574

N/A

0DataRank · unranked

4 citations

Mary Wilkinson, Lainie P. Martin, Amy Deery, Amanda Langsdale, Asnakech Bayable +6 more

Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae307

N/A

0DataRank · unranked

3 citations

Lova Sun, Ravi B. Parikh, Nadim Mahmud, Lainie P. Martin, Rebecca A. Hubbard +2 more

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.024

N/A

0DataRank · unranked

117 citations

Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin +17 more

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

10.1158/1078-0432.23814207.v1

N/A

0DataRank · unranked

0 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1602

N/A

0DataRank · unranked

32 citations

Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks +16 more